 Shandra Knight
Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 15 | 2024 | 464 | 2.260 |
Why?
| | Scleroderma, Systemic | 6 | 2024 | 93 | 1.350 |
Why?
| | Idiopathic Pulmonary Fibrosis | 7 | 2022 | 451 | 0.910 |
Why?
| | Alveolitis, Extrinsic Allergic | 4 | 2021 | 83 | 0.720 |
Why?
| | Mycobacterium kansasii | 3 | 2020 | 14 | 0.570 |
Why?
| | Mycobacterium Infections, Nontuberculous | 4 | 2022 | 335 | 0.540 |
Why?
| | Mycobacterium abscessus | 3 | 2020 | 98 | 0.500 |
Why?
| | Lung | 11 | 2024 | 3623 | 0.370 |
Why?
| | Bacteriuria | 2 | 2019 | 9 | 0.350 |
Why?
| | Asymptomatic Infections | 2 | 2019 | 23 | 0.340 |
Why?
| | Pulmonary Fibrosis | 2 | 2022 | 303 | 0.330 |
Why?
| | Administration, Intravenous | 2 | 2019 | 135 | 0.320 |
Why?
| | Injections | 2 | 2019 | 167 | 0.320 |
Why?
| | Drug Utilization | 2 | 2019 | 169 | 0.310 |
Why?
| | Urinary Tract Infections | 2 | 2019 | 135 | 0.310 |
Why?
| | Disease Management | 3 | 2019 | 566 | 0.290 |
Why?
| | Societies, Medical | 4 | 2023 | 701 | 0.280 |
Why?
| | Pneumonia, Ventilator-Associated | 2 | 2016 | 41 | 0.280 |
Why?
| | Anti-Infective Agents | 2 | 2019 | 227 | 0.280 |
Why?
| | Outpatients | 2 | 2019 | 324 | 0.270 |
Why?
| | Pneumonia, Bacterial | 2 | 2016 | 110 | 0.260 |
Why?
| | Biopsy | 7 | 2022 | 1078 | 0.250 |
Why?
| | Indoles | 2 | 2024 | 311 | 0.250 |
Why?
| | Cross Infection | 2 | 2016 | 204 | 0.240 |
Why?
| | Immunosuppressive Agents | 5 | 2024 | 682 | 0.220 |
Why?
| | Lymphocytes | 2 | 2020 | 346 | 0.210 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2020 | 1130 | 0.210 |
Why?
| | Disease Progression | 6 | 2024 | 2477 | 0.200 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2020 | 605 | 0.190 |
Why?
| | Humans | 36 | 2024 | 118257 | 0.190 |
Why?
| | Hypercapnia | 1 | 2020 | 50 | 0.190 |
Why?
| | Noninvasive Ventilation | 1 | 2020 | 30 | 0.180 |
Why?
| | Inhalation Exposure | 1 | 2020 | 87 | 0.180 |
Why?
| | Immunoglobulin G | 2 | 2021 | 785 | 0.180 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2020 | 56 | 0.180 |
Why?
| | Practice Guidelines as Topic | 4 | 2020 | 1433 | 0.180 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2020 | 124 | 0.170 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 665 | 0.170 |
Why?
| | Gastroesophageal Reflux | 1 | 2022 | 248 | 0.170 |
Why?
| | Cyclophosphamide | 3 | 2024 | 222 | 0.170 |
Why?
| | Bronchoscopy | 4 | 2022 | 246 | 0.170 |
Why?
| | Nontuberculous Mycobacteria | 4 | 2022 | 207 | 0.160 |
Why?
| | Home Care Services | 1 | 2020 | 215 | 0.150 |
Why?
| | Liver Diseases | 1 | 2020 | 282 | 0.150 |
Why?
| | Anti-Bacterial Agents | 4 | 2019 | 1514 | 0.150 |
Why?
| | Cardiomyopathies | 1 | 2020 | 298 | 0.140 |
Why?
| | Neurocognitive Disorders | 1 | 2016 | 25 | 0.140 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 690 | 0.140 |
Why?
| | Quality of Life | 5 | 2024 | 2355 | 0.140 |
Why?
| | Kidney Diseases | 1 | 2020 | 439 | 0.130 |
Why?
| | Mycobacterium avium Complex | 3 | 2020 | 92 | 0.130 |
Why?
| | United States | 9 | 2024 | 12491 | 0.130 |
Why?
| | Lung Diseases | 1 | 2022 | 709 | 0.130 |
Why?
| | Adult | 13 | 2022 | 31325 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 3 | 2022 | 2433 | 0.130 |
Why?
| | Influenza, Human | 1 | 2019 | 553 | 0.110 |
Why?
| | Rituximab | 2 | 2024 | 153 | 0.110 |
Why?
| | Hypertension, Pulmonary | 2 | 2021 | 1784 | 0.110 |
Why?
| | Antacids | 2 | 2022 | 15 | 0.110 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2016 | 232 | 0.110 |
Why?
| | Americas | 2 | 2019 | 22 | 0.090 |
Why?
| | Neutropenia | 2 | 2019 | 131 | 0.080 |
Why?
| | Drug Therapy | 2 | 2019 | 76 | 0.080 |
Why?
| | Transplant Recipients | 2 | 2019 | 148 | 0.080 |
Why?
| | HIV Infections | 1 | 2022 | 2454 | 0.080 |
Why?
| | Societies | 2 | 2017 | 42 | 0.070 |
Why?
| | Antimicrobial Stewardship | 2 | 2019 | 96 | 0.070 |
Why?
| | Communicable Diseases | 2 | 2019 | 132 | 0.070 |
Why?
| | Asthma | 1 | 2020 | 2143 | 0.070 |
Why?
| | Drug Resistance, Multiple, Bacterial | 2 | 2016 | 63 | 0.070 |
Why?
| | Bacteriological Techniques | 2 | 2016 | 66 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 1795 | 0.060 |
Why?
| | Lung Volume Measurements | 1 | 2023 | 46 | 0.060 |
Why?
| | Mycophenolic Acid | 1 | 2024 | 79 | 0.060 |
Why?
| | Vital Capacity | 1 | 2024 | 260 | 0.060 |
Why?
| | Spirometry | 1 | 2023 | 262 | 0.060 |
Why?
| | Prevalence | 2 | 2019 | 2321 | 0.050 |
Why?
| | Dyspnea | 1 | 2024 | 201 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2023 | 526 | 0.050 |
Why?
| | Prospective Studies | 2 | 2024 | 6443 | 0.050 |
Why?
| | Pyridones | 1 | 2022 | 119 | 0.050 |
Why?
| | Bronchial Provocation Tests | 1 | 2021 | 54 | 0.050 |
Why?
| | Bronchoalveolar Lavage | 1 | 2020 | 88 | 0.050 |
Why?
| | Serologic Tests | 1 | 2020 | 52 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 88 | 0.050 |
Why?
| | Lymphadenopathy | 1 | 2020 | 8 | 0.050 |
Why?
| | Mediastinum | 1 | 2020 | 21 | 0.050 |
Why?
| | Hypercalcemia | 1 | 2020 | 22 | 0.050 |
Why?
| | Medical History Taking | 1 | 2020 | 120 | 0.050 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2020 | 53 | 0.050 |
Why?
| | Exhalation | 1 | 2020 | 35 | 0.050 |
Why?
| | Aspartate Aminotransferases | 1 | 2020 | 94 | 0.050 |
Why?
| | Cryosurgery | 1 | 2020 | 54 | 0.040 |
Why?
| | Alanine Transaminase | 1 | 2020 | 151 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 533 | 0.040 |
Why?
| | Alkaline Phosphatase | 1 | 2020 | 158 | 0.040 |
Why?
| | Eye Diseases | 1 | 2020 | 78 | 0.040 |
Why?
| | Pulmonary Medicine | 1 | 2020 | 85 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3169 | 0.040 |
Why?
| | Endosonography | 1 | 2020 | 142 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 4684 | 0.040 |
Why?
| | Chemoprevention | 1 | 2019 | 89 | 0.040 |
Why?
| | Japan | 1 | 2018 | 97 | 0.040 |
Why?
| | Latin America | 1 | 2018 | 73 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 298 | 0.040 |
Why?
| | Sarcoidosis | 1 | 2020 | 130 | 0.040 |
Why?
| | Hemorrhage | 1 | 2022 | 606 | 0.040 |
Why?
| | Creatinine | 1 | 2020 | 491 | 0.040 |
Why?
| | Europe | 1 | 2018 | 355 | 0.040 |
Why?
| | Eosinophils | 1 | 2020 | 282 | 0.040 |
Why?
| | Echocardiography | 1 | 2020 | 556 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2020 | 443 | 0.040 |
Why?
| | Genomics | 1 | 2022 | 668 | 0.040 |
Why?
| | Pregnancy | 2 | 2019 | 5671 | 0.040 |
Why?
| | Aged | 3 | 2020 | 19594 | 0.040 |
Why?
| | Electrocardiography | 1 | 2020 | 555 | 0.040 |
Why?
| | Vitamin D | 1 | 2020 | 352 | 0.040 |
Why?
| | Seasons | 1 | 2019 | 461 | 0.040 |
Why?
| | Disease Outbreaks | 1 | 2019 | 322 | 0.030 |
Why?
| | Hemodynamics | 1 | 2021 | 1002 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2020 | 517 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2024 | 12929 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1237 | 0.030 |
Why?
| | Chronic Disease | 1 | 2020 | 1630 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2020 | 891 | 0.030 |
Why?
| | Calcium | 1 | 2020 | 1151 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1379 | 0.030 |
Why?
| | Child | 2 | 2019 | 19033 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 6368 | 0.020 |
Why?
| | Male | 3 | 2020 | 57476 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 6541 | 0.020 |
Why?
| | Female | 3 | 2020 | 61262 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2016 | 9319 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 18364 | 0.010 |
Why?
| | Middle Aged | 1 | 2020 | 27511 | 0.010 |
Why?
|
|
Knight's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|